Literature DB >> 20491142

[Correction of intracranial hypertension syndrome using hyperosmolar solutions in patients with severe brain damage (multicenter randomized clinical study)].

Iu S Polushin, V V Krylov, D V Svistov, A A Belkin, S S Petrikov, A V Shchegolev, I N Leĭderman, V I Shatalov, A M Alasheev, M V Golikov, Kh T Guseĭnova, E N Rudnik, A S Soldatov, A A Solodov, Iu V Titova.   

Abstract

The paper presents the results of a muticenter study of the effect of 3 hyperosmolar solutions (15% mannitol solution, 10% sodium chloride solution, and the combined solution HyperHAES containing 7.2% sodium chloride and hydroxyethyl starch 200/0.5) on the value of intracranial pressure (ICP) (invasive ICP monitoring) and systemic hemodynamic parameters (PiCCOplus) in 94 clinical cases of intracranial hypertension (ICP more than 20 mm Hg) in 25 patients with acute cerebral pathology (severe brain injury, aneurysmatic subarachnoid hemorrhage). Intravenous infusion of the solutions was found to induce a reduction in ICP; however, this was most pronounced (by 30-40%) and longer (up to 4 hours) when HyperHAES solution was used. This solution produced not only an osmotic, but also hemodynamic effect.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20491142

Source DB:  PubMed          Journal:  Anesteziol Reanimatol        ISSN: 0201-7563


  3 in total

1.  Hypertonic saline versus other intracranial pressure-lowering agents for people with acute traumatic brain injury.

Authors:  Han Chen; Zhi Song; Jane A Dennis
Journal:  Cochrane Database Syst Rev       Date:  2019-12-30

2.  Hypertonic saline versus other intracranial pressure-lowering agents for people with acute traumatic brain injury.

Authors:  Han Chen; Zhi Song; Jane A Dennis
Journal:  Cochrane Database Syst Rev       Date:  2020-01-17

Review 3.  Role of colloids in traumatic brain injury: Use or not to be used?

Authors:  Tumul Chowdhury; Ronald B Cappellani; Bernhard Schaller; Jayesh Daya
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2013-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.